Pathstone Holdings
SRPT icon

Pathstone Holdings’s Sarepta Therapeutics SRPT Stock Holding History

Pathstone Holdings’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,181
Closed -$586K – 2337
2025
Q1 		$586K Buy
9,181
+279
+3% +$29.4K ﹤0.01% 1643
2024
Q4 		$1.08M Buy
8,902
+1,785
+25% +$219K ﹤0.01% 1329
2024
Q3 		$889K Sell
7,117
-160
-2% -$22.1K ﹤0.01% 1437
2024
Q2 		$1.15M Buy
7,277
+226
+3% +$29K 0.01% 1247
2024
Q1 		$913K Buy
7,051
+2,441
+53% +$299K ﹤0.01% 1331
2023
Q4 		$445K Buy
+4,610
New +$442K ﹤0.01% 1583

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Pathstone Holdings's SRPT Position: Q2 2025 in Review

Pathstone Holdings sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 9,181 shares — an estimated $586K sold.

Pathstone Holdings first reported a position in SRPT in Q4 2023 and held it in 6 quarters. The position peaked at $1.15M in Q2 2024. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Pathstone Holdings reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Pathstone Holdings sold 9,181 Sarepta Therapeutics shares in Q2 2025, an estimated $586K.
  • Pathstone Holdings first reported a position in Sarepta Therapeutics in Q4 2023 and held it in 6 quarters.
  • Pathstone Holdings's Sarepta Therapeutics position peaked at $1.15M in Q2 2024.
  • 363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Pathstone Holdings's 13F filing for Q2 2025, filed 12 Aug 2025.